Trial Profile

A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exaluren (Primary)
Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Mucopolysaccharidosis I; Rett syndrome
Focus Pharmacokinetics
Sponsors Eloxx Pharmaceuticals

Most Recent Events

19 Mar 2021 Time frame for first endpoint changed from 8 days to 24 hours
20 Jan 2021 According to an Eloxx Pharmaceuticals media release, trial results enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients, has been published in the Journal of Clinical Pharmacology.
20 Jan 2021 Results published in an Eloxx Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com